Terry W Hermiston

Summary

Affiliation: Berlex Biosciences
Country: USA

Publications

  1. ncbi Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses
    Terry Hermiston
    Berlex Biosciences, Richmond, CA 94804 0099, USA
    Curr Opin Mol Ther 4:334-42. 2002
  2. ncbi A demand for next-generation oncolytic adenoviruses
    Terry Hermiston
    Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94806, USA
    Curr Opin Mol Ther 8:322-30. 2006
  3. ncbi Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses
    Maxine Bauzon
    Bayer HealthCare, Pharmaceuticals Division, Novel Technologies Department, 2600 Hilltop Drive, Richmond, CA 94806, USA
    Curr Opin Mol Ther 10:350-5. 2008
  4. ncbi Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development
    Terry W Hermiston
    Department of Gene Therapy, Berlex Biosciences, Richmond, CA 94941, USA
    Mol Ther 11:496-507. 2005
  5. ncbi Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes
    Terry W Hermiston
    Berlex Biosciences, Richmond, California 94804 0099, USA
    Cancer Gene Ther 9:1022-35. 2002
  6. ncbi Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression
    Fang Jin
    Gene Therapy Research Department, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA
    Mol Ther 12:1052-63. 2005
  7. ncbi Development and validation of a robust and versatile one-plasmid regulated gene expression system
    Paul Szymanski
    Department of Gene Technologies, Berlex Biosciences, Richmond, California, USA
    Mol Ther 15:1340-7. 2007
  8. ncbi Multigene expression from a replicating adenovirus using native viral promoters
    Maxine Bauzon
    Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA
    Mol Ther 7:526-34. 2003
  9. ncbi Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus
    Peter J Kretschmer
    Gene Therapy Research Department, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA
    Mol Ther 12:118-27. 2005
  10. doi Enhanced protein production using HBV X protein (HBx), and synergy when used in combination with XBP1s in BHK21 cells
    Fang Jin
    Department of Molecular Biology, Bayer HealthCare, Richmond, California 94806, USA
    Biotechnol Bioeng 105:341-9. 2010

Collaborators

  • Paul Szymanski
  • Ayyappan Nair
  • G M Rubanyi
  • Fang Jin
  • Maxine Bauzon
  • Peter J Kretschmer
  • Richard N Harkins
  • Irene Kuhn
  • Jinger Xie
  • Cecile Chartier
  • Shaoheng Ni
  • Paul Harden
  • Kerry Fisher
  • Len Seymour
  • Steve Thorne
  • Julie Nye
  • Tony Reid
  • Andre Lieber
  • Daniel Castro
  • Michael Karr
  • Lynda K Hawkins

Detail Information

Publications12

  1. ncbi Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses
    Terry Hermiston
    Berlex Biosciences, Richmond, CA 94804 0099, USA
    Curr Opin Mol Ther 4:334-42. 2002
    ....
  2. ncbi A demand for next-generation oncolytic adenoviruses
    Terry Hermiston
    Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94806, USA
    Curr Opin Mol Ther 8:322-30. 2006
    ..Many of these approaches and test systems may be applicable to other viral systems being developed as oncolytic agents...
  3. ncbi Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses
    Maxine Bauzon
    Bayer HealthCare, Pharmaceuticals Division, Novel Technologies Department, 2600 Hilltop Drive, Richmond, CA 94806, USA
    Curr Opin Mol Ther 10:350-5. 2008
    ..In this review, three genetic-based methods to increase the potency and efficacy of oncolytic viruses, in which human adenovirus is utilized as an example of a prototype oncolytic virus, are discussed...
  4. ncbi Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development
    Terry W Hermiston
    Department of Gene Therapy, Berlex Biosciences, Richmond, CA 94941, USA
    Mol Ther 11:496-507. 2005
    ....
  5. ncbi Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes
    Terry W Hermiston
    Berlex Biosciences, Richmond, California 94804 0099, USA
    Cancer Gene Ther 9:1022-35. 2002
    ..Several classes of therapeutic genes are outlined, and potential synergies and hurdles to their delivery from replicating viruses are discussed...
  6. ncbi Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression
    Fang Jin
    Gene Therapy Research Department, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA
    Mol Ther 12:1052-63. 2005
    ..In summary, splice acceptor sequences can be used to control transgene expression from endogenous Ad promoters and this represents a genomically economical approach to arming oncolytic Ads...
  7. ncbi Development and validation of a robust and versatile one-plasmid regulated gene expression system
    Paul Szymanski
    Department of Gene Technologies, Berlex Biosciences, Richmond, California, USA
    Mol Ther 15:1340-7. 2007
    ..Finally, a pBRES expression cassette was transferred to an adeno-associated virus (AAV) vector and shown to be capable of regulated gene expression in vivo for nearly 1 year...
  8. ncbi Multigene expression from a replicating adenovirus using native viral promoters
    Maxine Bauzon
    Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA
    Mol Ther 7:526-34. 2003
    ..Potential clinical implications are discussed...
  9. ncbi Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus
    Peter J Kretschmer
    Gene Therapy Research Department, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA
    Mol Ther 12:118-27. 2005
    ....
  10. doi Enhanced protein production using HBV X protein (HBx), and synergy when used in combination with XBP1s in BHK21 cells
    Fang Jin
    Department of Molecular Biology, Bayer HealthCare, Richmond, California 94806, USA
    Biotechnol Bioeng 105:341-9. 2010
    ..We explored the possibility of combinational engineering of HBx with XBP1s in BHK21 cells. Our data revealed that combinational engineering of HBx with XBP1s further enhances protein production compared with HBx or XBP1s alone...
  11. ncbi A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types
    Jinger Xie
    Novel Technologies Department, Bayer HealthCare Pharmaceutical, 2600 Hilltop Drive, Richmond, CA 94806, USA
    Toxicol In Vitro 22:261-6. 2008
    ..The different susceptibility of cell lines to the ligands commonly used in these inducible systems suggests that it is important to consider the effects of the inducers prior to their use in experimental in vitro cell culture systems...
  12. pmc Directed evolution generates a novel oncolytic virus for the treatment of colon cancer
    Irene Kuhn
    Novel Technologies, Bayer HealthCare, Richmond, California, United States of America
    PLoS ONE 3:e2409. 2008
    ..Consequently, new approaches to generating highly potent oncolytic viruses are needed. To address this need, we developed a new method that we term "Directed Evolution" for creating highly potent oncolytic viruses...